Leah Kuntz

The International Psychogeriatric Association shares opportunities to improve worldwide geriatric care.

What socio-cultural events impacted the older LGBTQ+ generations, and how do they inform their current mental health status?

Should a patient at the end of her life have access to psilocybin, even if it’s illegal?

The chief medical officer of Karuna shares his thoughts exclusively with Psychiatric Times.

The FDA has approved the New Drug Application for a once-daily ADHD treatment.

If approved, this formulation of sodium oxybate will be the first once-nightly oxybate treatment for daytime sleepiness.

A new study considers how the virus might enter the brain and cause cognitive issues.

If approved by the FDA, this treatment would be the first therapy for treating depressive episodes in both bipolar I and II disorder in 2 different forms.

An alcohol use disorder treatment has 4 potential advantages over existing treatments.

What black physicians have influenced the mental health field, changing it for good?

A study on a new Alzheimer disease vaccine lacks concrete numbers.

The American Heart Association released a statement recognizing the importance of the relationship between mental well-being and cardiovascular disease.

Is the purported “saddest day of the year” evidence-based?

The Department of Health and Human Services moves to reduce administrative procedural barriers to OUD treatment.

Researchers have discovered a gene signaling pathway associated with a higher risk for developing schizophrenia.

Improving physical activity levels and eating habits could help patients with schizophrenia.

In an ADAPT-2 study, a combination of injectable naltrexone and oral bupropion showed promise for methamphetamine users.

The RISE study results look promising.

Major psychiatry organizations condemn the actions and events of January 6th.

A new formulation of dexmedetomidine meets primary and secondary endpoints in recently completed study.

A new phase 3 trial recently started for the novel treatment troriluzole.

New developments in Alzheimer disease treatment and research.

The first and only transdermal patch for the treatment of adults with schizophrenia shows positive phase 3 trial results.

VistaGen Therapeutic’s grant application for PH10, an investigational therapeutic agent for the treatment of depression, has been approved.

Findings bring us closer to understanding schizophrenia that may enable clinicians to target symptoms.

Axsome Therapeutics released details from their COMET-SI trial for AXS-05, an oral investigational NMDA receptor.

Karuna Therapeutics shared exciting results from a Phase 2 trial on their lead agent.

Looking for holiday gifts that encourage mental well being?

A new study by The Trevor Project finds that welcoming environments can reduce suicide risk.

According to a recent study, certain product combinations of alcohol and cannabis may be less likely to cause negative consequences.